Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 12-Apr-24 4:05 PM View:  | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 11-Apr-24 | Sale | 54 | $6.74 | $363.96 | (< 1%) 70.9K to 70.85K | |
| 02-Feb-24 4:05 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale (Planned) | 2,590 | $8.86 | $22,947.40 | (3%) 83.31K to 80.72K | |
| 02-Feb-24 4:05 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale (Planned) | 2,590 | $8.86 | $22,947.40 | (3%) 78.86K to 76.27K | |
| 02-Feb-24 4:06 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 9,106 | $8.53 | $77,693.30 | (2%) 369.72K to 360.62K | |
| 02-Feb-24 4:05 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 4,195 | $8.53 | $35,788.80 | (4%) 103.7K to 99.5K | |
| 02-Feb-24 4:05 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 3,818 | $8.53 | $32,572.50 | (5%) 74.72K to 70.9K | |
| 02-Feb-24 4:05 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,174 | $8.53 | $18,546.60 | (4%) 60.25K to 58.07K | |
| 02-Feb-24 4:06 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale (Planned) | 10,016 | $8.86 | $88,741.80 | (3%) 360.62K to 350.6K | |
| 02-Feb-24 4:05 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,174 | $8.53 | $18,547.70 | (3%) 85.48K to 83.31K | |
| 02-Feb-24 4:05 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,174 | $8.53 | $18,547.90 | (3%) 81.03K to 78.86K | |
| 02-Feb-24 4:05 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 01-Feb-24 | Sale | 2,820 | $8.53 | $24,058.00 | (5%) 54.84K to 52.02K | |
| 02-Feb-24 4:05 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 41% 60.48K to 85.48K | |
| 02-Feb-24 4:05 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 71% 35.25K to 60.25K | |
| 02-Feb-24 4:05 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 45% 56.03K to 81.03K | |
| 02-Feb-24 4:05 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 13,500 | -- | -- | 33% 41.34K to 54.84K | |
| 02-Feb-24 4:06 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 135,000 | -- | -- | 58% 234.72K to 369.72K | |
| 02-Feb-24 4:05 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 32% 78.7K to 103.7K | |
| 02-Feb-24 4:05 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 31-Jan-24 | Grant | 25,000 | -- | -- | 50% 49.72K to 74.72K | |
| 25-Jan-24 4:10 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale | 853 | $9.07 | $7,735.35 | (2%) 50.57K to 49.72K | |
| 25-Jan-24 4:10 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale (Planned) | 2,062 | $8.96 | $18,475.50 | (3%) 62.55K to 60.48K | |
| 25-Jan-24 4:10 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale (Planned) | 2,062 | $8.96 | $18,475.50 | (4%) 58.1K to 56.03K | |
| 25-Jan-24 4:10 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale | 910 | $9.07 | $8,252.24 | (2%) 42.25K to 41.34K | |
| 25-Jan-24 4:10 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale (Planned) | 7,873 | $8.96 | $70,542.10 | (3%) 242.59K to 234.72K | |
| 25-Jan-24 4:10 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 23-Jan-24 | Sale | 1,559 | $9.07 | $14,137.60 | (2%) 80.26K to 78.7K | |
| 05-Jan-24 4:11 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 04-Jan-24 | Sale (Planned) | 440 | $9.17 | $4,034.80 | (1%) 35.69K to 35.25K | |
| 05-Jan-24 4:11 PM View: | Inrig Jula Chief Medical Officer | Travere Therapeutics, Inc. (TVTX) | 03-Jan-24 | Sale | 2,069 | $9.48 | $19,612.90 | (5%) 37.76K to 35.69K | |
| 04-Oct-23 4:05 PM View: | Heerma Peter Chief Commercial Officer | Travere Therapeutics, Inc. (TVTX) | 03-Oct-23 | Sale | 3,091 | $8.25 | $25,504.10 | (4%) 83.35K to 80.26K | |
| 05-Sep-23 8:10 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 05-Sep-23 | Sale (Planned) | 4,455 | $14.71 | $65,533.10 | (2%) 247.05K to 242.59K | |
| 05-Sep-23 8:15 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 05-Sep-23 | Sale | 457 | $14.71 | $6,722.56 | (< 1%) 51.03K to 50.57K | |
| 05-Sep-23 8:13 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 05-Sep-23 | Sale (Planned) | 1,815 | $14.71 | $26,698.70 | (3%) 62.99K to 61.17K | |
| 05-Sep-23 8:12 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 05-Sep-23 | Sale (Planned) | 1,815 | $14.71 | $26,698.70 | (3%) 59.91K to 58.1K | |
| 05-Sep-23 8:13 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 31-Aug-23 | Grant | 3,300 | -- | -- | 6% 59.69K to 62.99K | |
| 05-Sep-23 8:12 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 31-Aug-23 | Grant | 3,300 | -- | -- | 6% 56.61K to 59.91K | |
| 05-Sep-23 8:10 PM View: | Dube Eric M Chief Executive Officer Director | Travere Therapeutics, Inc. (TVTX) | 31-Aug-23 | Grant | 9,900 | -- | -- | 4% 237.15K to 247.05K | |
| 19-May-23 4:06 PM View: | Poole Sandra Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 36% 12.5K to 17.0K | |
| 19-May-23 4:05 PM View: | Coughlin Timothy P Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 12% 38.0K to 42.5K | |
| 19-May-23 4:05 PM View: | Meckler Jeffrey A Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 6% 70.0K to 74.5K | |
| 19-May-23 4:06 PM View: | Baynes Roy D. Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 22% 20.0K to 24.5K | |
| 19-May-23 4:05 PM View: | Orwin John A Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 25% 17.88K to 22.38K | |
| 19-May-23 4:05 PM View: | Bruhn Suzanne Louise Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 40% 11.25K to 15.75K | |
| 19-May-23 4:05 PM View: | Lyons Gary A Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 11% 40.0K to 44.5K | |
| 19-May-23 4:05 PM View: | Brinkley Ruth W Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 55% 8.25K to 12.75K | |
| 19-May-23 4:05 PM View: | Squarer Ron Director | Travere Therapeutics, Inc. (TVTX) | 17-May-23 | Grant | 4,500 | -- | -- | 25% 17.88K to 22.38K | |
| 12-May-23 4:06 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 11-May-23 | Sale (Planned) | 122 | $16.12 | $1,966.64 | (< 1%) 42.37K to 42.25K | |
| 12-May-23 4:14 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 10-May-23 | Sale | 455 | $16.59 | $7,548.45 | (< 1%) 51.49K to 51.03K | |
| 12-May-23 4:09 PM View: | Rote William E. Senior Vice President, R&D | Travere Therapeutics, Inc. (TVTX) | 10-May-23 | Sale (Planned) | 825 | $16.59 | $13,686.80 | (1%) 60.04K to 59.21K | |
| 12-May-23 4:11 PM View: | Reed Elizabeth E SVP, GC & Corporate Secretary | Travere Therapeutics, Inc. (TVTX) | 10-May-23 | Sale (Planned) | 825 | $16.59 | $13,686.80 | (1%) 57.44K to 56.61K | |
| 12-May-23 4:06 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 10-May-23 | Sale | 436 | $16.59 | $7,233.24 | (1%) 42.8K to 42.37K | |
| 13-Apr-23 4:07 PM View: | Cline Christopher R. Chief Financial Officer | Travere Therapeutics, Inc. (TVTX) | 11-Apr-23 | Sale | 47 | $21.49 | $1,010.03 | (< 1%) 51.53K to 51.49K | |
| 02-Feb-23 6:53 PM View: | Calvin Sandra SVP, Chief Accounting Officer | Travere Therapeutics, Inc. (TVTX) | 02-Feb-23 | Sale (Planned) | 360 | $22.42 | $8,071.20 | (< 1%) 43.16K to 42.8K |
